Connect with us

Business

Psilocybin Research Approved in Arizona Appropriations Act Budget

Published

on

The recently approved appropriations bill contains grant funds for psilocybin research.

Arizona senators voted to approve a general appropriations act 2023-2024 on May 10. Within the appropriations bill is a multitude of funding proposals from the governor’s office, which includes everything from Alzheimer’s disease research ($4.1 million), a newborn screening program ($12 million), and the Arizona nurse education investment pilot program ($15 million), but it also includes $5 million earmarked for psilocybin research.

A health care bill, SB-1726/HB-2816, recently receive a hearing on May 10 as well, which shows what that $5 million in research would go toward “research grants for whole mushroom psilocybin phase one, phase two and 41 phase three clinical trials that are capable of being approved by the 42 United States food and drug administration…” The bill cites a number of medical conditions, including PTSD, symptoms of long COVID-19, depression, anxiety disorders, and nine more.

If passed it would instruct the Department of Health Services to open up applications for research, which would be awarded no later than February 1 of each year. The department would be limited to spending a maximum of 2% of the money for psilocybin grant research each fiscal year.

Research subjects would specifically include “veterans, first responders, frontline health care workers … and persons from underserved communities.”

Protections are also included for both the grant receiver as well as any employees working on a study, stating that they “may not be charged with or prosecuted for possession … of psilocybin when the person is working on the clinical trial.”

A psilocybin research advisory council would be tasked to manage the program to provide “recommendations to the governor, the speaker of the House of Representatives, the president of the Senate and the department on psychedelic-assisted therapy based on current federal and state research policy.” It would be made up of multiple key individuals, including a member who holds a federal license to study psychedelics and is a licensed physician, a military veteran, an Arizona law enforcement officer, and a professor or researcher who specializes in psychedelic studies.

On February 13, legislators unanimously passed a different psilocybin research bill in the House Military Affairs & Public Safety Committee, which would have given $30 million in grants to psilocybin researchers. “Today HB 2486 (clinical research; psilocybin; grants; appropriation) passed MAPS Committee by a unanimous vote of 15-0! Thank you to brave bipartisan lawmakers sponsoring this bill to study veterans & first responders! @KevinPayne4AZ @TJShopeforAZ @JenLongdon @TraversforAZ,” said Dr. Sue Sisley, who is well known for her research work on cannabis and psychedelics. HB-2486 has not received any further discussion as of this writing.

While cannabis studies continue to grow, the number of psilocybin research efforts have been growing. In February, city officials in Ferndale, Michigan voted to decriminalize mushrooms as well as other psychedelic substances such as DMT and ayahuasca, and Utah officials introduced a psilocybin bill. In March, Nevada lawmakers introduced a psilocybin and MDMA research bill, and the Missouri House of Representatives approved a psilocybin research bill.

On May 10, Washington State Gov. Jay Inslee signed a bill that creates a psilocybin therapy pilot program, although he did so with a partial veto for specific sections. On that same day, the Connecticut House of Representatives approved a psilocybin decriminalization bill. 

Oregon is farthest ahead in terms of progress. Earlier this month, Oregon awarded its first license for a psilocybin service center, following the finalization of rules back in January. “This is such a historic moment as psilocybin services will soon become available in Oregon, and we appreciate the strong commitment to client safety and access as service center doors prepare to open,” said Oregon Psilocybin Services Section Manager Angie Albee.

Source: https://hightimes.com/news/psilocybin-research-approved-in-arizona-appropriations-act-budget/

Business

New Mexico cannabis operator fined, loses license for alleged BioTrack fraud

Published

on

New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.

The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.

Golden Roots operates the The Cannabis Revolution Dispensary.

The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.

The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.

Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.

After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.

In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.

The company requested a hearing, which the regulator scheduled for Sept. 1.

At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.

Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.

Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.

The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:

Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.

Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/

Continue Reading

Business

Marijuana companies suing US attorney general in federal prohibition challenge

Published

on

Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.

According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”

Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.

The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”

The companies want the case to go before the U.S. Supreme Court.

They hired prominent law firm Boies Schiller Flexner to represent them.

The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.

Similar challenges to the federal Controlled Substances Act (CSA) have failed.

One such challenge led to a landmark Supreme Court decision in 2005.

In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.

In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.

Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.

“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.

“Moreover, the facts on which those precedents are based are no longer true.”

Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”

While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.

“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”

Source: https://mjbizdaily.com/marijuana-companies-suing-us-attorney-general-to-overturn-federal-prohibition/

Continue Reading

Business

Alabama to make another attempt Dec. 1 to award medical cannabis licenses

Published

on

Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.

The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).

Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.

Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.

That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.

Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.

Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.

A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.

Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News